Growth and Adiposity in Newborns: The Influence of Prenatal Docosahexaenoic Acid (DHA) Supplementation
Completed
- Conditions
- Pregnancy; Nutritional Diseases
- Interventions
- Dietary Supplement: Docosahexaenoic acid
- Registration Number
- NCT03310983
- Lead Sponsor
- University of Kansas Medical Center
- Brief Summary
The purpose of this study is to learn if participants in the ADORE study (NCT02626299), who took a DHA supplement during pregnancy, see favorable body fat in their infants from birth to 24 months, and if excessive or appropriate weight gain during pregnancy impacts this result.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 254
Inclusion Criteria
- Agree to consume study capsules and a typical prenatal supplement of 200 mg DHA
- Available by telephone
Exclusion Criteria
- Expecting multiple infants
- Gestational age at baseline <12 weeks or >20 weeks
- Unable or unwilling to agree to consume capsules until delivery
- Unwilling to discontinue use of another prenatal supplement with DHA that contains ≥ 200 mg DHA
- Women with allergy to any component of DHA product (including algae), soybean oil or corn oil
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description ADORE Participants Docosahexaenoic acid Participants enrolled in the ADORE study are invited to participate in this study.
- Primary Outcome Measures
Name Time Method Infant Fat Mass (FM) 24 months Difference in FM in offspring exposed to high vs. low DHA and excessive vs. non-excessive GWG
- Secondary Outcome Measures
Name Time Method Central Fat Mass 24 months Difference in FM in offspring exposed to high vs. low DHA and excessive vs. non-excessive GWG
Trial Locations
- Locations (1)
The University of Kansas Medical Center
🇺🇸Kansas City, Kansas, United States